Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
A Longitudinal Study Investigating the Effects of Photobiomodulation (PBM) on Cognitive Function and Alzheimer's Disease (AD)-Related Biomarkers in Individuals With Mild Cognitive Impairment (MCI) or Dementia Due to AD
The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to provide topical heating to elevate tissue temperature for temporary relief of muscle and joint pain, muscle spasm and stiffness associated with arthritis. It also increases blood circulation and relaxes muscle tissue. This device is being used "off-label," meaning it will be used in a way that is different than its cleared use.
We want to learn whether this light treatment can improve executive function, and whether it changes certain inflammatory and neurodegeneration related signals in the blood. To do this, we will apply the photobiomodulation device to your forehead. We will also ask you questions and give you cognitive tests before and after light treatment. We will also collect blood samples before and after treatment.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Enrique Vargas Vargas, MD
- Phone Number: 972-281-7187
- Email: enrique.vargas@cshs.org
Study Contact Backup
- Name: Golnaz Yadollahikhales, MD
- Phone Number: 310-385-6016
- Email: Golnaz.Yadollahikhales@cshs.org
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- CSMC
-
Contact:
- Enrique Vargas, MD
- Phone Number: 972-281-7187
- Email: enrique.vargas@cshs.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed and dated informed consent form (either by subject or LAR)
- Willingness and ability to comply with all study procedures
- Age 55 to 89 years, inclusive
- Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis
- Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits
- Stable dose of Alzheimer's disease medications (e.g., donepezil, rivastigmine, memantine, galantamine) for at least 4 weeks prior to enrollment, if applicable
Exclusion Criteria:
- Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.)
- History of Seizures
- If patient holds neuroimaging showing space-occupying lesions
- If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages
- Current pregnancy or lactation (although unlikely in this population)
- Participation in another clinical trial or investigational drug within the past 30 days
- Active use of illicit substances or non-prescribed psychoactive drugs within the past 30 days.
- Severe dementia due to Alzheimer's disease or another etiology
- Physical or mental impairment that prevents the participant from complying with the cognitive testing battery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active photobiomodulation
1064nm photobiomodulation to be applied for 8 minutes total each session
|
1064nm transcranial photobiomodulation
|
|
Sham Comparator: Sham
only 5 seconds of photobiomodulation, to account for small amount of participants who reported an initial warm sensation upon stimulation
|
1064nm transcranial photobiomodulation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NIH Toolbox
Time Frame: Baseline measurements will be performed prior to intervention, post-treatment (week 5), and lastly at the 3-month follow-up visit
|
Three validated NIH Toolbox tasks:
|
Baseline measurements will be performed prior to intervention, post-treatment (week 5), and lastly at the 3-month follow-up visit
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glial Fibrillary Acidic Protein (GFAP)
Time Frame: Will be performed at baseline and at 3 month follow up
|
Plasma GFAP concentration (pg/ml) measure using the S-PLEX Assay
|
Will be performed at baseline and at 3 month follow up
|
|
Neurofilament Light Chain (NfL)
Time Frame: Baseline and 3-month follow up
|
Plasma Neurofilament Light Chain (NfL) concentration (pg/ml) measure using the S-PLEX Assay
|
Baseline and 3-month follow up
|
|
Total Tau
Time Frame: Baseline and 3-month follow up
|
Plasma total tau concentration (pg/ml) measure using the S-PLEX Assay
|
Baseline and 3-month follow up
|
|
Interferon-γ (IFN-γ)
Time Frame: Baseline and 3-month follow up
|
Plasma GFAP concentration (pg/ml) measure using the V-PLEX Assay
|
Baseline and 3-month follow up
|
|
Interleukin-1β (IL-1β)
Time Frame: Baseline and 3-month follow up
|
Plasma IL-1β concentration measured using the V-PLEX assay
|
Baseline and 3-month follow up
|
|
Tumor Necrosis Factor-α (TNF-α)
Time Frame: Baseline and 3-month follow up
|
Plasma TNF-α concentration (pg/ml) measured using the V-PLEX assay
|
Baseline and 3-month follow up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Golnaz Yadollahikhales, MD, Cedars Siinai Medical Center Department of Neurology
Publications and helpful links
General Publications
- Zhu G, Tong Q, Ye X, Li J, Zhou L, Sun P, Liang F, Zhong S, Cheng R, Zhang J. Phototherapy for Cognitive Function in Patients With Dementia: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2022 Jun 30;14:936489. doi: 10.3389/fnagi.2022.936489. eCollection 2022.
- Luo G, Zhang J, Song Z, Wang Y, Wang X, Qu H, Wang F, Liu C, Gao F. Effectiveness of non-pharmacological therapies on cognitive function in patients with dementia-A network meta-analysis of randomized controlled trials. Front Aging Neurosci. 2023 Mar 2;15:1131744. doi: 10.3389/fnagi.2023.1131744. eCollection 2023.
- Chan AS, Lee TL, Yeung MK, Hamblin MR. Photobiomodulation improves the frontal cognitive function of older adults. Int J Geriatr Psychiatry. 2019 Feb;34(2):369-377. doi: 10.1002/gps.5039. Epub 2018 Dec 10.
- Su M, Nizamutdinov D, Liu H, Huang JH. Recent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer's Disease. Int J Mol Sci. 2023 May 25;24(11):9272. doi: 10.3390/ijms24119272.
- Gonzalez-Lima, F. (2021). Neuroprotection and Neurocognitive Augmentation by Photobiomodulation. In: Opris, I., A. Lebedev, M., F. Casanova, M. (eds) Modern Approaches to Augmentation of Brain Function. Contemporary Clinical Neuroscience. Springer, Cham. https://doi.org/10.1007/978-3-030-54564-2_9
- Vargas E, Barrett DW, Saucedo CL, Huang LD, Abraham JA, Tanaka H, Haley AP, Gonzalez-Lima F. Beneficial neurocognitive effects of transcranial laser in older adults. Lasers Med Sci. 2017 Jul;32(5):1153-1162. doi: 10.1007/s10103-017-2221-y. Epub 2017 May 2.
- Boyer D, Hu A, Warrow D, Xavier S, Gonzalez V, Lad E, Rosen RB, Do D, Schneiderman T, Ho A, Munk MR, Jaffe G, Tedford SE, Croissant CL, Walker M, Ruckert R, Tedford CE. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. Retina. 2024 Mar 1;44(3):487-497. doi: 10.1097/IAE.0000000000003980.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00004349
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.